Table 2.
Investigator-assessed RRs.
| Response | Entire study cohort | LDH ≤ ULN | LDH > ULN | No prior therapy | Prior therapy | BTS < 5 cm | BTS ≥ 5 cm |
|---|---|---|---|---|---|---|---|
| CR | 14/34 (41%) | 10/18 (56%) | 4/16 (25%) | 8/17 (47%) | 6/17 (35%) | 8/16 (50%) | 6/18 (33%) |
| PR | 15/34 (46%) | 5/18 (27%) | 10/16 (63%) | 7/17 (41%) | 8/17 (47%) | 5/16 (31%) | 10/18 (56%) |
| SD | 3 (8%) | 2/18 (11%) | 1/16 (6%) | 2/17 (12%) | 1/17 (6%) | 2/16 (13%) | 1/18 (6%) |
| PD | 2 (5%) | 1/18 (6%) | 1/16 (6%) | 0 | 2/17 (11%) | 1/16 (6%) | 1/18 (5%) |
| N | 34 | 18 | 16 | 17 | 17 | 16 | 18 |
| ORR | 29/34 (85%) | 15/18 (83%) | 14/16 (88%) | 15/17 (88%) | 14/17 (82%) | 14/16 (81%) | 16/18 (89%) |
Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.